Compare OSPN & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | BNTC |
|---|---|---|
| Founded | 1991 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 411.4M |
| IPO Year | 2000 | 2020 |
| Metric | OSPN | BNTC |
|---|---|---|
| Price | $11.33 | $13.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.67 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 492.4K | 100.6K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.66% | N/A |
| EPS Growth | 28.77 | ★ 80.94 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $5.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $9.85 |
| 52 Week High | $18.13 | $17.15 |
| Indicator | OSPN | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 70.22 |
| Support Level | $10.20 | $12.79 |
| Resistance Level | $11.54 | $14.21 |
| Average True Range (ATR) | 0.36 | 0.75 |
| MACD | 0.09 | 0.33 |
| Stochastic Oscillator | 92.92 | 86.19 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.